Amgen's Vectibix hits PhIII survival goal in previously treated mCRC patients

Amgen's ($AMGN) Vectibix already has an FDA nod for first-line treatment of wild-type KRAS metastatic colorectal cancer. And now, new data show, it's hit its goals in previously treated patients, too. The treatment trumped best supportive care in patients who had failed to respond to chemo, posting a statistically significant improvement in overall survival to nail the primary endpoint of a Phase III study. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.